Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the…

By M. Agulnik, E. Cohen, R. Cohen, E. Chen, E. Vokes, S. Hotte, E. Winquist, S. Laurie, D. Hayes, J. Dancey and 7 more. 2007

Subfields: Oncology, Otorhinolaryngology, Pharmacology

Citations in the corpus

• Current landscape and future directions of therapeutic approaches for adenoid cystic carcinoma of the salivary glands (Review) (2025, unknown): “Previous studies on cetuximab, gefitinib and lapatinib inhibiting both EGFR and HER2 did not change the disease course substantially in patients with ACC (15,65).”